| http://www.w3.org/ns/prov#value | - UMN Pharma obtained the rights to vaccine development for FluBlok in various Asian countries, including Japan, China, and South Korea, from Protein Sciences Corporation, and subsequently set about to develop UMN-0502 as its own seasonal influenza vaccine.
|
